What are the typical clinical presentation and diagnostic workup for carcinoid tumors in adults?

Presentation and Diagnosis of Carcinoid Tumours

Carcinoid tumors typically present either incidentally (40-45% of cases) or with non-specific respiratory/gastrointestinal symptoms, and diagnosis requires histological confirmation with neuroendocrine markers plus biochemical and functional imaging workup.

Clinical Presentation

Location-Specific Presentations

Bronchopulmonary carcinoids present with:

• Non-specific respiratory symptoms (cough, hemoptysis, dyspnea) in central tumors 1, 2
• Incidental findings on chest imaging in peripheral tumors 2
• Cushing's syndrome from ACTH secretion (minority of cases) 3, 4

Gastrointestinal carcinoids present with:

• Carcinoid syndrome (only 10% of all carcinoid patients, but 30% of small intestinal NETs): episodic flushing, explosive watery diarrhea, bronchospasm, and cardiac valvular disease (tricuspid regurgitation/pulmonary stenosis in 50-66% with syndrome) 5, 3, 6
• Abdominal pain and altered bowel habits (often misdiagnosed as irritable bowel syndrome) 7
• Incidental discovery during endoscopy or imaging 8
• Emergency presentation with bleeding or perforation (rare) 9

Critical caveat: Carcinoid syndrome only occurs when vasoactive substances bypass hepatic metabolism—typically requiring liver metastases or retroperitoneal disease, as portal circulation normally metabolizes these hormones 5, 3.

Diagnostic Workup

1. Histological Confirmation (Essential)

Obtain tissue via the most accessible route 1, 2:

• Bronchial carcinoids: Endobronchial biopsy or surgical resection (preferred over cytology to differentiate typical from atypical) 4
• GI carcinoids: Endoscopic biopsy (gastroscopy, colonoscopy, EUS as appropriate) 7, 5

Immunohistochemistry must demonstrate 1:

• Chromogranin A
• Synaptophysin
• Neuron-specific enolase (NSE)

Histological classification determines prognosis 1:

• Typical carcinoid: <2 mitoses/2mm², no necrosis (5-year survival 80%)
• Atypical carcinoid: 2-10 mitoses/10HPF, focal necrosis (5-year survival 60%)

2. Biochemical Markers

Order based on tumor location and symptoms 1, 10, 5:

For all carcinoids:

• Plasma chromogranin A (general NET marker, elevated in most cases) 1, 8, 5
  • Pitfall: Can be falsely elevated with proton pump inhibitors, renal/hepatic insufficiency 8
  • Note: Limited sensitivity (62%, range 25-93%) in lung carcinoids specifically 4

For suspected carcinoid syndrome (GI/lung with metastases):

• 24-hour urine 5-HIAA (metabolite of serotonin, highly specific) 10, 8, 5, 3
  • Critical dietary restrictions: Avoid avocados, bananas, cantaloupe, eggplant, pineapples, plums, tomatoes, kiwi, walnuts, coffee, alcohol, and smoking for 48 hours before collection 8

For hormone-related symptoms:

• ACTH (Cushing's syndrome in bronchial/thymic carcinoids) 1, 3
• Gastrin, insulin, glucagon, VIP (pancreatic NETs) 10

3. Imaging Studies

Anatomical imaging 1, 7, 5:

• Multiphase CT or MRI (essential—NETs are hypervascular and can appear isodense on single-phase CT) 3
• Chest CT for bronchopulmonary primaries and lung metastases 1
• Bronchoscopy ± endoscopic ultrasound for bronchial tumors 1
• Endoscopy (EGD, colonoscopy, capsule endoscopy) for GI primaries 7, 5

Functional imaging 1, 7, 5:

• Somatostatin receptor scintigraphy (Octreoscan) or preferably SSTR-PET/CT: 80% of typical carcinoids express somatostatin receptors; superior for detecting primary tumor and metastases 1, 7, 4
  • SSTR-PET should replace Octreoscan when available 4
• FDG-PET: Limited role; may be useful if SSTR imaging negative, but should be avoided in typical carcinoids 4, 11

4. Staging

Use standard TNM staging for organ of origin 1, 10, 5:

• No specific TNM system exists for bronchial/thymic carcinoids—use lung cancer staging 1
• GI NETs: Use European Neuroendocrine Tumor Society TNM classification with grading based on Ki-67 proliferation index 10, 5

Diagnostic Algorithm

1. Suspect carcinoid based on clinical presentation or incidental imaging finding
2. Obtain tissue diagnosis with immunohistochemistry for neuroendocrine markers
3. Measure biochemical markers: Chromogranin A (all cases) + 24-hour urine 5-HIAA (if GI/lung with suspected syndrome) + hormone-specific tests if symptomatic
4. Perform multiphase CT/MRI of primary site and potential metastatic sites
5. Add SSTR-PET/CT (or Octreoscan if unavailable) for disease localization and burden assessment
6. Complete staging with appropriate endoscopic/bronchoscopic evaluation

Common pitfall: Diagnostic delay is frequent because symptoms are non-specific and often attributed to other conditions (IBS, asthma, menopause for flushing) 9. Maintain high index of suspicion in patients with unexplained chronic diarrhea, flushing, or incidental lung/GI masses.

Management should occur in specialized centers with multidisciplinary NET expertise given the rarity and complexity of these tumors 2, 12, 13.